PMID- 31065667
OWN - NLM
STAT- MEDLINE
DCOM- 20200312
LR  - 20200312
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 152
IP  - 2
DP  - 2019 Jul 5
TI  - Routine Solid Phase Multiplex Anti-HLA Antibody Tests Predict Platelet 
      Refractoriness.
PG  - 146-154
LID - 10.1093/ajcp/aqz024 [doi]
AB  - OBJECTIVES: No validated screening methods identify patients at risk for human 
      leukocyte antigen (HLA) alloimmune-mediated platelet refractoriness (alloPR). We 
      determined if bead-based HLA antibody tests could predict risk of developing HLA 
      alloPR. METHODS: Hematopoietic progenitor cell transplant patients screened for 
      HLA antibodies without prior refractoriness were identified. Phenotype bead 
      screening results were compared between patients who later did and did not 
      develop alloPR. RESULTS: Seven of 27 patients identified subsequently developed 
      alloPR. The panel reactive antibody (PRA) and mean fluorescence intensity (MFI) 
      of the 10 most reactive beads in the initial screen were significantly higher 
      among patients who later developed alloPR (P < .001). Specifically, PRA of more 
      than 30% and mean MFI of 1,500 or more in the most reactive beads identified 
      at-risk patients. Administration of HLA-compatible platelets yielded significant 
      posttransfusion count increments compared with routine platelets. CONCLUSIONS: 
      HLA antibody screening by phenotype bead assay may prospectively identify at-risk 
      patients for the development of alloPR. However, clinical trials are needed to 
      validate these findings.
CI  - (c) American Society for Clinical Pathology, 2019. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Pena, Jeremy Ryan A
AU  - Pena JRA
AD  - Division of Transfusion and Laboratory Medicine, Department of Pathology, Beth 
      Israel Deaconess Medical Center, Boston, MA.
AD  - Harvard Medical School, Boston, MA.
FAU - Makar, Robert S
AU  - Makar RS
AD  - Blood Transfusion Service, Department of Pathology, Massachusetts General 
      Hospital, Boston.
AD  - Harvard Medical School, Boston, MA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Aged
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Isoantibodies/*immunology
MH  - Male
MH  - Middle Aged
MH  - Platelet Transfusion/*adverse effects
MH  - Thrombocytopenia/*etiology/immunology
OTO - NOTNLM
OT  - HLA antibody
OT  - Platelet refractoriness
OT  - Platelet transfusion
EDAT- 2019/05/09 06:00
MHDA- 2020/03/13 06:00
CRDT- 2019/05/09 06:00
PHST- 2019/05/09 06:00 [pubmed]
PHST- 2020/03/13 06:00 [medline]
PHST- 2019/05/09 06:00 [entrez]
AID - 5486588 [pii]
AID - 10.1093/ajcp/aqz024 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2019 Jul 5;152(2):146-154. doi: 10.1093/ajcp/aqz024.